A polyvalent vaccine for high-risk prostate patients: "Are more antigens better?"

Cancer Immunology, Immunotherapy

Volumn 56, Issue 12, 2007, Pages 1921-1930

  Slovin, Susan F ^a   Ragupathi, Govind ^a   Fernandez, Celina ^a   Diani, Meghan ^a   Jefferson, Matthew P ^a   Wilton, Andrew ^a   Kelly, W Kevin ^b   Morris, Michael ^a   Solit, David ^a   Clausen, Henrik ^c   Livingston, Philip ^a   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibodies; Antigen; Polyvalent; Prostate cancer; PSA; Vaccine

Indexed keywords

CANCER VACCINE; CARBOHYDRATE VACCINE; GLOBO H ANTIGEN; GM2 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; LE ANTIGEN; MUC 1 32MER ANTIGEN; PROSTATE SPECIFIC ANTIGEN; QS 21; TF ANTIGEN; TN ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RELAPSE; CELL STRAIN MCF 7; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLOW CYTOMETRY; FLU LIKE SYNDROME; FLUORESCENCE ACTIVATED CELL SORTING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 34848896345     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0335-y     Document Type: Article

References (32)

1. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281:1591-1597
2. Ragupathi R, Slovin SF, Adluri S et al (1999) A fully synthetic globo H carbohydrate vaccine induces a focused humoral response to prostate cancer patients: a proof of principle. Angew Chem Int Ed 38:563-566
3. Slovin SF, Ragupathi G, Musselli C et al (2003) Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine (Tn) conjugate vaccine. J Clin Oncol 21:4292-4298
4. Ragupathi G Koganty RR, Qiu DX et al (1998) A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl)cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J 15:217-221
5. Seeberger P, Cirillo PF, Hu S et al (1996) Synthesis of the pentasaccharide core structure of asparagine-linked glycoprotein oligosaccharides by the glycal assembly method. Enantiomer 1:311-323
6. Danishefsky SJ, Bilodeau MT (1996) Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. Angew Chem Int Ed Engl 35:1380-1419
7. Helling F, Zhang S, Shang A et al (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788
8. Gilewski T, Adluri S, Zhang S et al (2000) Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693-1701
9. Livingston P (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-166
10. Slovin SF, Ragupathi G, Adluri S et al (1999) Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96:5710-5715
11. Slovin S, Ragupathi G, Clarke T et al (2003) Multivalency in a phase II prostate cancer (PC) vaccine trial: are more antigens better? Proc Am Soc Clin Oncol 22:167 (Abstr#671)
12. Kim SK, Ragupathi G, Musselli C, Livingston PO (1999) Comparison of the effect of different immunological adjuvants on the antibody and T cell response to immunization with MUC1-KLH and GD3-KLH conjugate vaccines. Vaccine 18:597-603
13. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in viro and is absent in MUC1 transgenic mice. J Immunol 161:5500-5506
14. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: Protectin and control of the cell surface. Nat Rev 4:45-60
15. Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC 1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58:4079-4081
16. Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human t cells. Nat Med 2:1367-1370
17. Wykes M, MacDonald KP, Tran M et al (2002) Quin RJ, Xing PX, Gendler SJ, et al. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukoc Biol 72:692-701
18. 197. Infect Immun 39:233-238
19. Kurika S (1996) Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 14:1239-1242
20. Barington T, Gyhrs A, Kristensen K, Heilmann C (1994) Opposite effect of actively and passively acquired immunity to the carrier on response of human infants to Haemophilus influenzae type b conjugate vaccine. Infect Immun 62:9-14
21. Peters CC, Tenbergen-Meeks AM, Poolman JT et al (1974) Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59:3504-3510
22. Sarvas H, Makela O, Toivanen P, Toivanen A (1974) Effect of carrier preimmunization on the anti-hapten response in chicken. Scand J Immunol 3:455-460
23. Fattom A, Cho YH, Chu C et al (1999) Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17:126-133
24. Barington T, Skettrup M, Juul L, Heilman C (1993) Non-epitope-specific suppression of antibody response to Haemophilus influenzae type b conjugate vaccine by preimmunization with vaccine components. Infect Immun 61:432-438
25. Cleland JL, Kensil CR, Lim A et al (1996) Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci 85:22-28
26. Armstrong JL, Ragupathi G, Powell S et al (2003) Preliminary data of vaccination of high risk breast cancer (BC) patients with a heptavalent antigen: keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21. Proc Am Soc Clin Oncol 675:168 (Abstr#675)
27. Slovin SF, Wilton A, Heller G, Scher HI (2005) Time to detectable metastatic disease in patients with a rising PSA after surgery or radiation therapy. Clin Cancer Res 11:8669-8673
28. Simons JW, Mikhak B, Chang JF et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160-5168
29. ® vaccine for prostate cancer. Urol Oncol 24(5):419-424
30. Livingston PO, Cunningham-Rundles S, Marfleet G et al (1987) Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 6:392-403
31. Gerritsen W, Van den Eertwegh AJ, De Gruijl T et al (2006) A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). Proc Am Soc Clin Oncol 24:100 (Abstr#2500)
32. Scher HI, Eisenberger M, D'Amico AV et al (2004) Eligibility and outcomes, reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22:537-56